LDLR and atherosclerosis: We show that transient APAP administration provided Cypor-deficient Ldlr+/+ hepatocytes a selective advantage to expand in the liver to levels within the desired threshold for expected clinical benefit, resulting in reduced lipid levels, but not providing protective effects against atherosclerosis development in Ldlr−/− mice.